Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
H.LichtensteinM
Heres what the clinical evidence shows: Study Scope: 900+ participants across 6 randomized, double-blind, placebo-controlled trials Safety Profile: Indistinguishable from placebo in tolerability assessments Serious Events: Zero serious adverse events attributed to AOD-9604 Withdrawals: No treatment-related discontinuations in any trial Common Effects: Mild headache and minor GI symptoms at rates similar to placebo IGF-1 Impact: No effect on insulin-like growth factor-1 levels Metabolic Safety: No negative impact on glucose metabolism or insulin sensitivity Immunogenicity: Zero participants developed anti-AOD9604 antibodies The following analysis provides complete details on the clinical trial evidence supporting AOD-9604s favorable safety profile
The benzyl alcohol content inhibits microbial growth, which is why preserved diluents carry a longer in-use shelf life than unpreserved sterile water
Variables such as body weight, calorie intake, energy expenditure, glucose, and fat oxidation, insulin, and glycerol were measured before and after treatment with AOD9604 and hGH
